Full-Time
Marketplaces Advertising Manager
Advertising, Marketplaces
Posted on 9/1/2025
Pattern Bioscience
51-200 employees
AI-driven rapid bacterial ID and AST
No salary listed
Melbourne VIC, Australia
Hybrid
Hybrid working options available.
 Growth & Marketing (2) |
|---|
| , |
- 2+ years of Amazon Advertising implementation in an agency
- 1+ years of ecommerce implementation across off-platform Performance Marketing channels is a bonus
- A background in developing relationships with both internal and client side stakeholders at various levels
- Confidence in presenting new business opportunities
- Advanced knowledge of key platforms: Amazon Ads, eBay Ads and DSPs
- Excellent attention to detail, communication skills
- 1 year + of line management experience
- Experience pitching for new business
- Experience with Google Docs/Drive & Analytics tools
- Execution of marketplace advertising channels, particularly Amazon Ads, eBay Ads & Amazon DSP across your allocated client sets
- Completing client forecasts with responsibilities for KPIs
- Implementing to ensure allocated clients are following best in class practices, not just including channel implementation but additional processes such as forecasting and budget management
- Help problem solve/troubleshoot implementation issues and improve client performance to exceed client KPIs
- Managing a team of junior strategists who carry out the implementation and account manage clients
- Be involved in the account management of key clients
- Actively stay up to date with new marketplace advertising content trends and platform updates
- Assist in preparing & presenting new business proposals to showcase our strategic thinking, best practice approach and product offering
- Working closely with the performance marketing team on project work, such as audits and strategies
- 1+ years of ecommerce implementation across off-platform Performance Marketing channels is a bonus
Pattern Bioscience develops rapid clinical diagnostics that identify bacterial infections and determine antibiotic resistance. Its system uses single-cell analysis with AI pattern recognition to deliver definitive ID/AST results in about four hours. The product suite includes diagnostic devices, consumables, service contracts, and software for AI analysis. By speeding and improving accuracy, Pattern Bioscience aims to help hospitals reduce inappropriate antibiotic use and combat antibiotic resistance.
Company Size
51-200
Company Stage
Series D
Total Funding
$91.6M
Headquarters
Austin, Texas
Founded
2016
Simplify's Take
What believers are saying
- $43M Series D funding from AMR Action Fund supports FDA 510(k) submission.
- $40.9M BARDA contract accelerates pneumonia and bacteremia panel development.
- Over 1,000 samples enrolled in multi-center trial for Q3 regulatory push.
What critics are saying
- Accelerate Diagnostics' PhenoVue captures market with FDA-cleared 3-hour AST.
- BioFire's FilmArray dominates ICU syndromic testing, sidelining single-pathogen focus.
- Clinical trial failure by mid-2026 exhausts Series D runway, halting launch.
What makes Pattern Bioscience unique
- Digital CultureTM enables culture-free phenotypic ID/AST in four hours.
- Single-cell analysis captures all resistance mechanisms unlike genotypic tests.
- Pneumonia ID/AST Panel targets critically ill patients with FDA Breakthrough Designation.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Pattern Bioscience who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
Paid Holidays
401(k) Company Match
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 1%Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.
To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology.
Pattern Bioscience secures $28.7 million in Series C financing to accelerate development of first-of-its-kind infectious disease diagnostic platform
Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.
Including the Series C round, Pattern has now raised $68 million to date, the company said in a statement.